New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia

Blood Cells, Molecules, and Diseases

Volumn 43, Issue 1, 2009, Pages 88-97

  Roeder, Ingo ^a,b   d'Inverno, Mark ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chronic myeloid leukemia; Computer simulation; Hematopoietic stem cells; Mathematical modelling

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ALPHA INTERFERON; BCR ABL PROTEIN; DASATINIB; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; PEPTIDE VACCINE; PR1 PEPTIDE VACCINE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; WT1 PEPTIDE VACCINE;

CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL DIVISION; CELL FATE; CELL RENEWAL; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; COMPUTER PREDICTION; COMPUTER SIMULATION; CONFERENCE PAPER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MATHEMATICAL MODEL; MINIMAL RESIDUAL DISEASE; MULTIPOTENT STEM CELL; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; REGULATORY MECHANISM; STOCHASTIC MODEL; SYSTEMS BIOLOGY;

CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL;

EID: 68649103701     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.03.003     Document Type: Conference Paper

References (70)

1. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
2. Borthakur G., and Cortes J.E. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int. J. Hematol. 79 (2004) 411-419
3. Deininger W. Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. J. Cancer Res. Clin. Oncol. 130 (2004) 59-72
4. Kantarjian M., and Cortes J. New strategies in chronic myeloid leukemia. Int. J. Hematol. 83 4 (2006) 289-293
5. Hochhaus A., Weisser A., La Rosee A., et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 14 (2000) 998-1005
6. Bhatia R., Holtz M., Niu N., et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101 (2003) 4701-4707
7. Goldman J., and Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?. Leuk. Lymphoma 47 (2006) 1-7
8. Martinelli G., Iacobucci I., Soverini S., et al. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukemia patients in treatment with imatinib as a guide to clinical management. Hematol. Oncol. 24 (2006) 196-204
9. Wodarz D., and Komarova N.L. Emergence and prevention of resistance against small molecule inhibitors. Semin. Cancer Biol. 15 (2005) 506-514
10. Abbott L.H., and Michor F. Mathematical models of targeted cancer therapy. Br. J. Cancer 95 (2006) 1136-1141
11. Roeder I., and Glauche I. Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses. J. Mol. Med. 86 (2007) 17-27
12. Morrison J., and Weissman I.L. Heterogeneity of hematopoietic stem cells: implications for clinical applications. Proc. Assoc. Am. Physicians 107 (1995) 187-194
13. Morrison J., White P.M., Zock C., et al. Prospective identification, isolation by flow cytometry, and in vivo self-renewal of multipotent mammalian neural crest stem cells. Cell 96 (1999) 737-749
14. Goodell A., Mckinney-Freeman S., Camargo F.D., et al. Isolation and characterization of side population cells. Methods Mol. Biol. 290 (2005) 343-352
15. Yilmaz H., Kiel M.J., Morrison S.J., et al. SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity. Blood 107 (2006) 924-930
16. Heisenberg W. Über den anschaulichen Inhalt der quantentheoretischen Kinematik und Mechanik. Z. Phys. 43 (1927) 197
17. Potten S., and Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 110 (1990) 1001-1020
18. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4 (1978) 7-25
19. Calvi M., Adams G.B., Weibrecht K.W., et al. Osteoblastic cells regulate the hematopoietic stem cell niche. Nature 425 (2003) 841-846
20. Zhang J., Niu C., Ye L., et al. Identification of the hematopoietic stem cell niche and control of the niche size. Nature 425 (2003) 836-841
21. Kiel J., and Morrison S.J. Maintaining hematopoietic stem cells in the vascular niche. Immunity 25 (2006) 862-864
22. Moore A., and Lemischka I.R. Stem cells and their niches. Science 311 (2006) 1880-1885
23. Xie Y., Yin T., Wiegraebe W., et al. Detection of functional hematopoietic stem cell niche using real-time imaging. Nature 457 (2008) 91-101
24. Wagers J., Christensen J.L., Weissman I.L., et al. Cell fate determination from stem cells. Gene Ther. 9 (2002) 606-612
25. Bryder D., Rossi D.J., and Weissman I.L. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am. J. Pathol. 169 (2006) 338-346
26. Majeti R., Park C.Y., and Weissman I.L. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 1 (2007) 635-645
27. Habibian K., Peters S.O., Hsieh C.C., et al. The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit. J. Exp. Med. 188 (1998) 393-398
28. Sato T., Laver J.H., and Ogawa M. Reversible expression of CD34 by murine hematopoietic stem cells. Blood 94 (1999) 2548-2554
29. Aliotta M., Sanchez-Guijo F.M., Dooner G.J., et al. Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. Stem Cells 25 (2007) 2245-2256
30. Chang H., Hemberg M., Barahona M., et al. Transcriptome-wide noise controls lineage choice in mammalian progenitor cells. Nature 453 (2008) 544-547
31. Dooner S., Aliotta J.M., Pimentel J., et al. Conversion potential of marrow cells into lung cells fluctuates with cytokine-induced cell cycle. Stem Cells Dev. 17 (2008) 207-219
32. Wilson A., Laurenti E., Oser G., et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135 (2008) 1118-1129
33. Loeffler M., and Potten C.S. Stem cells and cellular pedigrees - a conceptual introduction. In: Potten C.S. (Ed). Stem Cells (2007), Academic Press, Cambridge 1-27
34. Loeffler M., and Roeder I. Tissue stem cells: definition, plasticity, heterogeneity, self-organization and models - a conceptual approach. Cells Tissues Organs 171 (2002) 8-26
35. Roeder I., and Loeffler M. A novel dynamic model of hematopoietic stem cell organization based on the concept of within-tissue plasticity. Exp. Hematol. 30 (2002) 853-861
36. Fuchs E., and Segre J.A. Stem cells: a new lease on life. Cell 100 (2000) 143-155
37. Kosodo Y., Roper K., et al. Asymmetric distribution of the apical plasma membrane during neurogenic divisions of mammalian neuroepithelial cells. EMBO J. 23 (2004) 2314-2324
38. Huttner B., and Kosodo Y. Symmetric versus asymmetric cell division during neurogenesis in the developing vertebrate central nervous system. Curr. Opin. Cell Biol. 17 (2005) 648-657
39. Kantarjian M., Talpaz M., Giles F., et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med. 145 (2006) 913-923
40. Catlin N., Guttorp P., and Abkowitz J.L. The kinetics of clonal dominance in myeloproliferative disorders. Blood 106 (2005) 2688-2692
41. Roeder I., Horn M., Glauche I., et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12 (2006) 1181-1184
42. M.W. Drummond, N. Heaney, J. Kaeda, F.E. Nicolini, R.E. Clark, G. Wilson, P. Shepherd, J. Tighe, L. McLintock, T. Hughes, T.L. Holyoake, A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia (in press), doi: 10.1038/leu.2009.43.
43. Michor F., Hughes T.P., Iwasa Y., et al. Dynamics of chronic myeloid leukemia. Nature 435 (2005) 1267-1270
44. Dingli D., and Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 24 (2006) 2603-2610
45. Michor F., Iwasa Y., and Nowak M.A. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 14931-14934
46. Horn M., Loeffler M., and Roeder I. Mathematical modeling of genesis and treatment of chronic myeloid leukemia. Cells Tissues Organs 188 (2008) 236-247
47. Kim P.S., Lee P.P., and Levy D. A PDE model for imatinib-treated chronic myelogenous leukemia. Bull. Math. Biol. 70 (2008) 1994-2016
48. Bose S., Deininger M., Gora-Tybor J., et al. The presence of BCR-ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease. Blood 92 (1998) 3362-3367
49. Biernaux C., Loos M., Sels A., et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86 (1995) 3118-3122
50. Brassesco S. Leukemia/lymphoma-associated gene fusions in normal individuals. Genet. Mol. Res. 7 (2008) 782-790
51. Michor F. The long-term response to imatinib treatment of CML. Br. J. Cancer 96 (2007) 979-980
52. Graham M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
53. Graham M., Vass J.K., Holyoake T.L., et al. Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. Stem Cells 25 (2007) 3111-3120
54. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
55. Ritchie E., and Nichols G. Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy. Curr. Cancer Drug Targets. 6 (2006) 645-657
56. Komarova L., and Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9714-9719
57. Muller C., Lahaye T., Hochhaus A., et al. Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells. Dtsch. Med. Wochenschr. 127 (2002) 2205-2207
58. Jorgensen G., Copland M., and Holyoake T.L. Granulocyte-colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 103 (2005) 210-211
59. Esser M.A.G., Offner S., Blanco-Bose W.E., et al. IFNα activates dormant HSCs in vivo. Nature (2009) doi:10.1038/nature07815
60. Copland M., Pellicano F., Richmond L., et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111 (2008) 2843-2853
61. Mailander V., Scheibenbogen C., Thiel E., et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18 (2004) 165-166
62. Oka Y., Tsuboi A., Taguchi T., et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13885-13890
63. Yong S., Keyvanfar K., Eniafe R., et al. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22 (2008) 1721-1727
64. Rezvani K., Yong A.S., Mielke S., et al. Leukemia-associated antigen specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111 (2008) 236-242
65. Chen I., Maecker H.T., and Lee P.P. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 111 (2008) 5342-5349
66. Kim P.S., Lee P.P., and Levy D. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLOS Comput. Biol. 4 (2008) e1000095
67. Komarova L., and Wodarz D. Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor. Popul. Biol. 72 (2007) 523-538
68. Kirkland A. A phase space model of hemopoiesis and the concept of stem cell renewal. Exp. Hematol. 32 (2004) 511-519
69. d'Inverno M., and Luck M. Understanding Agent Systems. 2nd ed. (2004), Springer, London
70. M. d'Inverno, P. Howells, S. Montagna, et al., Agent-based Modelling of Stem Cells, in: A.M. Uhrmacher (ed.), Multi-Agent Systems: Simulation and Applications, Taylor & Francis Group, London (in press).